Keros Therapeutics, Inc.NASDAQ: KROS

Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2026 Financial Results

· Issued by Keros Therapeutics, Inc. via GlobeNewswire

Summary by 6ix AI

Keros Therapeutics, a clinical-stage drug developer focused on disorders linked to faulty signaling of the transforming growth factor-beta (TGF-β) protein family, reported net income of $14.2 million for the quarter ended September 30, 2026, compared with a net loss of $7.3 million a year earlier.

Key details

  • Keros says the increase of approximately $21.4 million was primarily due to revenue recognized in 2026 related to its license agreement with Takeda.
  • Research and development expenses were $20.5 million, compared with $19.5 million in the third quarter of 2025. General and administrative expenses fell to $6.7 million from $10.1 million, primarily due to lower compensation costs and professional fees.
  • Cash and cash equivalents were $259.5 million as of September 30, 2026, compared with $287.4 million as of December 31, 2025.
  • In September 2026, the first patient was dosed in a Phase 2 (mid-stage) clinical trial of rinvatercept in patients with Duchenne muscular dystrophy.
  • Keros nominated KER-206, a lab-stage protein designed to bind certain TGF-β family proteins that regulate bone remodeling, for further investigation. In October 2026, it presented a poster on a research version at the American Society for Bone and Mineral Research 2026 Annual Meeting.

What’s still pending

  • Keros expects to report initial data from the Phase 2 rinvatercept trial in the first half of 2027.
  • Based on current operating assumptions, Keros expects its cash to fund operating expenses and capital expenditures into the second half of 2028.

6ix AI wrote this summary from the release below and checked it against the release.

  • First patient dosed in Phase 2 clinical trial of rinvatercept in patients with Duchenne muscular dystrophy in September 2026
  • Nominated KER-206, a novel ligand trap designed to bind select TGF-β ligands to regulate bone remodeling, from nonclinical pipeline for further investigation
  • Cash runway expected into the second half of 2028

LEXINGTON, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-β”) family of proteins, today provided a business update and reported financial results for the quarter ended September 30, 2026.

“We are excited to continue advancing our pipeline across both clinical and nonclinical development, building on our understanding of TGF-β biology to develop potential new treatments for patients,” said Jasbir S. Seehra, Ph.D., President and Chief Executive Officer. “We remain focused on disciplined execution of our strategic priorities as we work to advance our programs and build on the potential of our pipeline.”

Recent Program Updates

  • Rinvatercept for the treatment of Duchenne muscular dystrophy (“DMD”): In September 2026, Keros announced the first patient was dosed in the Phase 2 clinical trial of rinvatercept in patients with DMD. Keros expects to announce initial data from this trial in the first half of 2027.
  • KER-206: In October 2026, Keros presented a nonclinical poster on a research version of KER-206, or RKER-206, at the American Society for Bone and Mineral Research 2026 Annual Meeting.
    • KER-206 is a nonclinical asset designed to bind select ligands from the TGF-β superfamily, including activin A, activin B, GDF8 and GDF11, which regulate bone remodeling through effects on differentiation and activity of bone-resorptive cells (osteoclasts) and bone-forming cells (osteoblasts). Through inhibition of these TGF-β ligands, the Company believes that KER-206 has the potential to increase bone mass and improve skeletal integrity in disorders characterized by pathological bone loss.

Third Quarter 2026 Financial Results

Keros reported net income of $14.2 million in the third quarter of 2026 as compared to a net loss of $7.3 million in the third quarter of 2025. The increase of approximately $21.4 million was primarily due to revenue recognized in 2026 related to Keros' license agreement with Takeda.

Research and development expenses were $20.5 million for the third quarter of 2026 as compared to $19.5 million for the same period in 2025. The increase of $1.0 million was primarily due to the additional research and development efforts to support the advancement of Keros’ pipeline, partially offset by decreased elritercept-related research and development expenses as activities transitioned to Takeda during 2025.

General and administrative expenses were $6.7 million for the third quarter of 2026 as compared to $10.1 million for the same period in 2025. The decrease of $3.4 million was primarily due to a decrease in compensation costs and a decrease in professional fees.

Keros’ cash and cash equivalents as of September 30, 2026 was $259.5 million compared to $287.4 million as of December 31, 2025. Based on current operating assumptions, Keros expects that its cash and cash equivalents as of September 30, 2026 will enable Keros to fund its operating expenses and capital expenditure requirements into the second half of 2028.

About Keros Therapeutics, Inc.

Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-β family of proteins. Keros is a leader in understanding the role of the TGF-β family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including skeletal muscle, bone, adipose, heart tissue and blood. By leveraging this understanding, Keros has discovered and is developing protein therapeutics that have the potential to provide meaningful and potentially disease-modifying benefit to patients. Keros’ lead product candidate, rinvatercept, is being developed for the treatment of DMD and for the treatment of amyotrophic lateral sclerosis. Keros’ most advanced product candidate, elritercept, is being developed for the treatment of cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and in patients with myelofibrosis.

Cautionary Note Regarding Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “continue,” “expect,” “believe,” “will,” “may,” “potential,” or similar expressions are intended to identify forward-looking statements. Examples of these forward-looking statements include statements concerning: Keros’ expectations regarding its growth, strategy, progress and the advancement of its clinical and nonclinical pipeline; the development plans and potential therapeutic benefits of its product candidates; the design, objectives and timing of its clinical trials for rinvatercept; the potential of KER-206 to    increase bone mass and improve skeletal integrity in disorders characterized by pathological bone loss; and Keros’ expected cash runway and ability to fund its operating expenses and capital expenditure requirements. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: Keros’ limited operating history and historical losses; Keros’ ability to raise additional funding to complete the development and any commercialization of its product candidates; Keros’ dependence on the success of its product candidates, rinvatercept and elritercept; that Keros may be delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar uses; Keros’ ability to obtain, maintain and protect its intellectual property; and Keros’ dependence on third parties in connection with manufacturing, clinical trials and nonclinical studies.

These and other risks are described more fully in Keros’ filings with the Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s Quarterly Report on Form 10-Q, filed with the SEC on August 3, 2026, and its other documents subsequently filed with or furnished to the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, Keros undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Investor Contact:

Justin Frantz
[email protected]
617-221-6042

KEROS THERAPEUTICS, INC.
Condensed Consolidated Statements of Operations
(In thousands, except share and per share data)
(Unaudited)
THREE MONTHS ENDED
SEPTEMBER 30,
NINE MONTHS ENDED
SEPTEMBER 30,
2026202520262025
REVENUE:
Service and other revenue$9$4,262$376$38,321
License revenue40,00010,00040,000205,355
Total revenue40,00914,26240,376243,676
OPERATING EXPENSES:
Research and development(20,491)(19,519)(58,919)(111,731)
General and administrative(6,700)(10,127)(25,453)(35,106)
Total operating expenses(27,191)(29,646)(84,372)(146,837)
INCOME (LOSS) FROM OPERATIONS12,818(15,384)(43,996)96,839
OTHER INCOME (EXPENSE), NET
Interest income, net55—55—
Dividend income2,2206,9336,84220,845
Other expense, net(168)(253)(394)(812)
Total other income, net2,1076,6806,50320,033
Income (loss) before income taxes14,925(8,704)(37,493)116,872
Income tax (provision) benefit(772)1,424(772)(6,397)
Net income (loss)$14,153$(7,280)$(38,265)$110,475
Net income (loss) attributable to common stockholders—basic and diluted$14,153$(7,280)$(38,265)$110,475
Weighted-average shares of common stock outstanding — basic19,886,09740,623,36419,773,04740,598,777
Weighted-average shares of common stock outstanding — diluted20,341,14040,623,36419,773,04741,202,371
Net income (loss) per share of common stock — basic$0.71$(0.18)$(1.94)$2.72
Net income (loss) per share of common stock — diluted$0.70$(0.18)$(1.94)$2.68
KEROS THERAPEUTICS, INC.
Condensed Consolidated Balance Sheets
(In thousands, except share and per share data)
(Unaudited)
SEPTEMBER 30,
2026
DECEMBER 31,
2025
ASSETS
CURRENT ASSETS:
Cash and cash equivalents$259,464$287,415
Accounts receivable20,0003,567
Prepaid expenses and other current assets5,92022,202
Current income tax receivable2,2502,250
Total current assets287,634315,434
Operating lease right-of-use assets14,88716,841
Property and equipment, net3,3904,297
Restricted cash1,4491,449
Other long-term assets11—
TOTAL ASSETS$307,371$338,021
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Accounts payable$3,787$1,967
Current portion of operating lease liabilities2,6952,408
Accrued expenses and other current liabilities8,76116,039
Current tax liability615—
Total current liabilities15,85820,414
Operating lease liabilities, net of current portion12,41514,475
Total liabilities28,27334,889
STOCKHOLDERS' EQUITY:
Preferred stock, par value of $0.0001 per share; 10,000,000 shares authorized as of September
30, 2026 and December 31, 2025; no shares issued and outstanding
——
Series A junior participating preferred stock, par value of $0.0001 per share; 500,000 authorized
as of September 30, 2026 and December 31, 2025; no shares issued and outstanding
——
Common stock, par value of $0.0001 per share; 200,000,000 shares authorized as of
September 30, 2026 and December 31, 2025; 41,103,773 shares issued and 19,830,671 shares outstanding as of
September 30, 2026 and 40,670,466 shares issued and 19,543,706 shares outstanding as of December 31, 2025
44
Treasury stock, at cost; 21,273,102 shares as of September 30, 2026 and 21,126,760 shares as of December 31, 2025(386,211)(384,558)
Additional paid-in capital1,185,3351,169,451
Accumulated deficit(520,030)(481,765)
Total stockholders' equity279,098303,132
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY$307,371$338,021

View original source (GlobeNewswire)Keros Therapeutics, Inc. on 6ix

In the deck

Story so far

Earlier from Keros Therapeutics

Later from Keros Therapeutics

All Keros Therapeutics news releases